- Page 1 and 2: Annual Report 2002 Roche Group Annu
- Page 3 and 4: Group Performance at a Glance Sales
- Page 5 and 6: Roche Group Annual Report and Group
- Page 7 and 8: The sale of the Vitamins and Fine C
- Page 9 and 10: While continuing with the successfu
- Page 11 and 12: in biotechnology. At the beginning
- Page 13 and 14: emain stable. Given the volatility
- Page 15 and 16: Board of Directors as of 1 January
- Page 17 and 18: Executive Committee from 1 January
- Page 19 and 20: persons closely associated with the
- Page 21: usinesses through targeted acquisit
- Page 25 and 26: also posted double-digit gains. Alt
- Page 27 and 28: Western Europe. In November this no
- Page 29 and 30: Transplantation - strong growth for
- Page 31 and 32: ing positive decisions on both fili
- Page 33 and 34: Research and development - substant
- Page 35 and 36: Substantially expanded pipeline Ind
- Page 37 and 38: oncology portfolio, the roll-out of
- Page 39 and 40: Diagnostics Division in brief chang
- Page 41 and 42: Helping to shape the future. Roche
- Page 43 and 44: thing from glucose self-monitoring
- Page 45 and 46: Centralized Diagnostics. Sales by o
- Page 47 and 48: The global roll-out of Cobas TaqMan
- Page 49 and 50: Vitamins and Fine Chemicals Divisio
- Page 51 and 52: division outperformed expectations
- Page 53 and 54: People and the Environment Human re
- Page 55 and 56: worldwide the opportunity to purcha
- Page 57 and 58: Safety and Environmental Protection
- Page 59 and 60: Social Involvement The many faces o
- Page 61 and 62: ‘We do not intend to make a profi
- Page 63 and 64: Financial Review Figures reported F
- Page 65 and 66: Treasury and Financing During 2002
- Page 67 and 68: Operating profit: Double-digit incr
- Page 69 and 70: Pharmaceuticals: Operating profit a
- Page 71 and 72: Net income in millions of CHF On a
- Page 73 and 74:
Foreign currency translation effect
- Page 75 and 76:
The adjusted basis The concept of t
- Page 77 and 78:
in millions of CHF Reconciliation o
- Page 79 and 80:
Consolidated balance sheet in milli
- Page 81 and 82:
Consolidated cash flow statement in
- Page 83 and 84:
Foreign currency translation Most G
- Page 85 and 86:
Deferred income tax is provided, us
- Page 87 and 88:
Provisions Provisions are recognise
- Page 89 and 90:
Changes effective 1 January 2001 Se
- Page 91 and 92:
Liquidity risk Group companies need
- Page 93 and 94:
Total Core Vitamines and Pharmaceut
- Page 95 and 96:
of which the Group’s majority int
- Page 97 and 98:
6. Chugai On 10 December 2001, Roch
- Page 99 and 100:
The fair value adjustments to inven
- Page 101 and 102:
Vitamin case Following the settleme
- Page 103 and 104:
10. Employee benefits in millions o
- Page 105 and 106:
The Group operates defined benefit
- Page 107 and 108:
12. Financial income (expense), net
- Page 109 and 110:
Income tax assets and liabilities A
- Page 111 and 112:
Patents, licences, trademarks 2002
- Page 113 and 114:
18. Other long-term assets in milli
- Page 115 and 116:
25. Equity Share capital At the Ann
- Page 117 and 118:
28. Minority interests in millions
- Page 119 and 120:
The carrying value of the Group’s
- Page 121 and 122:
2002 2001 Foreign currency derivati
- Page 123 and 124:
33. Cash flow statement in millions
- Page 125 and 126:
Report of the Group Auditors To the
- Page 127 and 128:
1995 1996 1997 c) 1998 1999 2000 20
- Page 129 and 130:
Additions to property, plant and eq
- Page 131 and 132:
Number of shares and non-voting equ
- Page 133 and 134:
Outstanding issues Summarised issue
- Page 135 and 136:
Balance sheet at 31 December in mil
- Page 137 and 138:
Participations The major participat
- Page 139 and 140:
Report of the Statutory Auditors To
- Page 141 and 142:
120° 30° 150° 90° 60° 30° 0°
- Page 143 and 144:
Garden City, 70.000 GBP | Roche Reg
- Page 145 and 146:
Diagnostics 27% Sales by division 1